Single Patient Compassionate Use of X-PACT in Salvage Treatment of Prostate Cancer
Due to the subject's lack of conventional treatment options, a treatment plan using X-PACT administered intra-tumorally is proposed.
X-PACT (X-ray Psoralen Activated Cancer Therapy) is comprised of a phosphor device (an energy modulation agent), methoxsalen sterile solution (a psoralen), X-ray energy and represents a potential new approach for the treatment of solid tumors.
Methoxsalen is a psoralen found in the seeds of the Ammi majus (Umbelliferae) plant.
Importantly, methoxsalen (whether formulated as the sterile solution [Uvadex®] or as a hard gelatin capsule [8-MOP®]) can promote a strong long-term clinical response, as observed in the treatment of cutaneous T cell lymphoma (CTCL) utilizing extracorporeal photopheresis (ECP) and is approved by the United States Food and Drug Administration [US FDA] for this indication. In ECP, malignant CTCL cells are irradiated with UVA light in the presence of methoxsalen and then re-administered to the patient.
X-PACT may offer the potential for local control of primary or metastatic disease via administration of the combination product of methoxsalen and powerful energy converters
(Phosphors) when activated by x-ray beam. In addition, there is numerous data in support of an immunogenic role for activated methoxsalen. The cytotoxic and immunogenic effects of psoralens are often attributed to psoralen mediated photo-adduct DNA damage [1]. A principle mechanism underlying the long term immunogenic clinical response likely derives from psoralen induced tumor cell cytotoxicity and uptake of the apoptotic cells by immature dendritic cells, in the presence of inflammatory cytokines [2, 3 4, 5]. However, photochemical modification of proteins and other cellular components can also impact the antigenicity and potential immunogenicity of treated cells [6]. The diversity and potency of psoralen application is further illustrated by recent success using psoralen in the development of virus vaccines [7]. The immunogenic activity of methoxsalen supports a potential abscopal effect for X-PACT particularly as it incorporates both radiation and an immunotherapeutic.
Study Overview
Study Type
Expanded Access Type
- Individual Patients
Contacts and Locations
Study Locations
-
-
District of Columbia
-
Washington D.C., District of Columbia, United States, 20016
- Available
- Kimmel Cancer Center at Johns Hopkins at Sibley Memorial Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
The patient is willing and able to provide informed consent. Only the patient for whom this clinical study/experimental treatment was designed will be given the investigational drug under the treatment of the PI. No other patient is authorized to participate in or to receive treatment under this treatment protocol.
Exclusion Criteria:
Not applicable
Study Plan
How is the study designed?
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Panagis Galiatsatos, MD, Johns Hopkins University
Study record dates
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SIBCOM2502sp
- IRB00482834 (Other Identifier: JHM IRB)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.